. 2022 Jun 21;2022(6):CD006404. doi: 10.1002/14651858.CD006404.pub4

3. Serious adverse events.

Study	Pyronaridine‐artesunate	Comparator(s)
Kayentao 2012	Severe malaria (1)^a	Artemether‐lumefantrine ‐
Nelwan 2015	Head trauma (1)^a Typhoid fever (1)^b Nephrolithiasis (1)^b	Artesunate only Metacarpal fracture (1)^a Acute gastroenteritis (1)^a Suspected ureteric stone (1)^b Dihydroartemisinin‐piperaquine Dengue fever (1)^a
Poravuth 2011	Pyrexia (1)^a Typhoid fever (1)^a	Chloroquine ‐
Ringwald 1996	‐	‐
Ringwald 1998	‐	‐
Roth 2018a	‐	‐
Rueangweerayut 2012	Autoimmune haemolytic anaemia (1)^a Cholera (1)^a Pneumonia (1)^a Acute pyelonephritis (1)^a Wound infection (1)^a Abortion (1)^a Depression (1)^a	Mefloquine plus artesunate Cerebral malaria (1)^a Seizure (1)^c Grand mal seizure (1)^c
Tshefu 2010	Parotitis (1)^a Typhoid fever (1)^a Urinary tract infection (1)^a	Artemether‐lumefantrine Cerebral malaria (1)^a Immunosuppression (1)^a
Sagara 2018^d	Elevated ALT (2)^c Elevated AST (2)^c Transaminases increased (4)^c Drug‐induced liver injury (1)^c Hypercreatininaemia (1)^c	Artemether‐lumefantrine Drug‐induced liver injury (1)^c Toxic epidermal necrolysis (1)^c Artesunate‐amodiaquine Drug‐induced liver injury (1)^c Transaminases increased (2)^c

Abbreviations: ALT: alanine aminotransferase; AST: aspartate aminotransferase.

^aJudged by study authors as unrelated to drug. ^bJudged by study authors as unlikely to be related to drug. ^cJudged by study authors as treatment‐related. ^dThe nature of the serious adverse events judged to be unrelated to drug is not reported. Some of the listed events in the comparator groups may have occurred in comparisons with dihydroartemisinin‐piperaquine, but we were unable to extract data in relation to this.